Acceleron Pharma (XLRN) |
|
120.95 -4.93 (-3.92%)
|
01-27 02:43 |
|
Open: |
125.43 |
Pre. Close: |
125.88 |
|
High:
|
126.635 |
Low:
|
120.0026 |
|
Volume:
|
228,672 |
Market Cap:
|
7,287M |
|
|
|
|
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
126.998 - 127.702 |
127.702 - 128.274 |
|
Low:
|
117.884 - 118.853 |
118.853 - 119.64 |
|
Close:
|
119.523 - 120.962 |
120.962 - 122.132 |
|
Technical analysis |
as of: 2021-01-26 4:50:37 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 148.77 One year: 159.14 |
| Support: |
Support1: 113.01 Support2: 94.02 |
| Resistance: |
Resistance1: 127.37 Resistance2: 136.25 |
| Pivot: |
123.30 |
| Moving Average: |
MA(5): 124.51 MA(20): 124.09
MA(100): 115.00  MA(250): 102.70 |
| MACD: |
MACD(12,26): 0.31 Signal(9): 0.60 |
| Stochastic oscillator: |
%K(14,3): 53.40 %D(3): 57.79 |
| RSI: |
RSI(14): 45.20 |
| 52-week: |
High: 136.25 Low: 66.44 Change(%): 51.6 |
| Average Vol(K): |
3-Month: 31066 10-Days: 33710 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.XLRN has closed above bottom band by 35.7%. Bollinger Bands are 5.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 25 Jan 2021
Acceleron Pharma Inc. (XLRN) Soars 1.03% on January 25 - Equities.com
Mon, 25 Jan 2021
Acceleron Pharma Inc. (NASDAQ:XLRN) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Tue, 19 Jan 2021
Acceleron Pharma Inc. (XLRN) Soars 4.98% on January 19 - Equities.com
Tue, 19 Jan 2021
Raymond James Boosts Acceleron Pharma (NASDAQ:XLRN) Price Target to $160.00 - MarketBeat
Tue, 19 Jan 2021
Analysts’ Top Healthcare Picks: Acceleron Pharma (XLRN), Zymeworks (ZYME) - Smarter Analyst
Fri, 15 Jan 2021
Noteworthy Friday Option Activity: PATK, XLRN, NET - Nasdaq
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
60 |
| Shares Float (M) |
53 |
|
% Held by Insiders
|
12.18 |
|
% Held by Institutions
|
90.06 |
|
Shares Short (K)
|
2,930 |
|
Shares Short P. Month (K)
|
3,510 |
Stock Financials |
|
EPS
|
-2.400 |
|
EPS Est This Year
|
-2.690 |
|
EPS Est Next Year
|
-2.280 |
|
Book Value (p.s.)
|
14.910 |
|
Profit Margin
|
-124.73 |
|
Operating Margin
|
-127.64 |
|
Return on Assets (ttm)
|
-11.5 |
|
Return on Equity (ttm)
|
-19.4 |
|
Qtrly Rev. Growth
|
436.1 |
|
Gross Profit (p.s.)
|
-1.327 |
|
Sales Per Share
|
1.759 |
|
EBITDA (p.s.)
|
-2.182 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-108 |
|
Levered Free Cash Flow (M)
|
-67 |
Stock Valuations |
|
PE Ratio
|
-50.40 |
|
PEG Ratio
|
|
|
Price to Book value
|
8.11 |
|
Price to Sales
|
68.75 |
|
Price to Cash Flow
|
-67.19 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
